Mesoblast says remestemcel-L will continue to be in demand
MELBOURNE: Mesoblast chairman Joseph Swedish says the company’s rock star drug remestemcel-L will continue to
MELBOURNE: Mesoblast chairman Joseph Swedish says the company’s rock star drug remestemcel-L will continue to